Clay Siegall endeavors to enhance the lives of cancer patients through biomedicine. He uses research and innovation to develop solutions for the patients and reduce their suffering. Siegall has 15 patents and has published several research findings and over 70 related articles.
Dr. Siegall supports legislations that help make the process of developing patient therapists efficient. Current therapies are not as effective as there are possibilities of relapse. He is encouraged by the nation’s efforts in prioritizing funding for biomedical research and approves of the current FDA model.
Dr. Clay Siegall is the Chairman, President, co-founder, and CEO, of Seattle Genetics. His leadership oversaw the creation of antibody cancer therapies such as ADCETRIS. He has also been on the fore front raising capital for the company and has since raised over 1.2 billion dollars through public-private partnerships and IPOs. Before Seattle Genetics, he worked with the National Cancer Institute, the National Institutes of Health, and Bristol-Myers Squibb Pharmaceutical Research Institute.
Seattle Genetics came into the market in 1998, when distinguishing chemotherapy meant for cancer cells and that for normal cells was a daunting task. The objective of the of the company was to improve the lives of people battling cancer through initiating better therapies that cater for current unmet needs. In depth research and pharmaceutical development, innovation, and passion helped transform Seattle into a top company in the antibody-drug conjugates sector. ADCTERIS is now globally used. The company has also acquired strategic licenses for the ADC technology with global medical manufacturing and distribution companies such as GlaxoSmithKline and has generated over 350 million dollars. 20 or more ADCs are now using their technology for clinical development.
Currently, Seattle Genetics is working on changing the existing treatment plan for Hodgkin Lymphoma by using ADCs with existing chemotherapies. They have been improving Adcetris to replace Bleomycin to treat the disease. According to the Investments Business daily, the Echelon-1 is set to increase Seattle Genetic’s value.
Clay sits on the Alder Bio Pharmaceuticals Board of Directors. He holds a Generics P.H.D and B.S in Zoology from George Washington University and the University of Maryland. The University of Maryland recognized Dr. Siegall as the alumnus of the year 2013 in Computer, Natural Science, and Math. Ernst &Young recognized him as the Pacific Northwest entrepreneur of 2012.
One of the biggest reasons that Mikhail Blagosklonny chose to be an oncologist was so that he would be able to help people. He has always been interested in how he can help and that has played a huge role in his career. One of the things that he has done in his practice, Oncotarget, is what has set him apart and made him so much different than other oncologists. He uses Oncotarget to help other practitioners so that they can help their patients and make a big difference in the world of cancer. He even hopes that one day he will be able to use it to help cure cancer.There are many oncologists who have practices around the country and who work hard with each other to ensure that they are helping, but they may not always have had a direct link to each other. This is what Oncotarget has done to them. They now have a link that keeps them together and helps them make sure that they are experiencing all of the things that will make their lives better. They know that they can help and that they can provide people with the options that they need.
The people who benefit the most from these cancer research methods and the peer review publication are the patients. They are able to benefit from it because they get new treatments and they can get things that will help them to grow with the experiences that they have. Thanks to the way that Mikhail Blagosklonny set up Oncotarget, all doctors who are a part of it will be able to experience the different benefits of it. They can then take these things and offer them to all of their patients to help them get the treatment that they deserve to have.Oncotarget is much different from other types of publications because the peer review aspect of it allows doctors from different areas to talk with each other to help figure out what is going on in these situations.
Mikhail Blagosklonny knew this and knew that he wanted to make his publication part of a group of doctors who know what they can do and who know what they are going to be able to make better for themselves. He has tried to allow different doctors to connect with each other so that they can try new things and help them get the best benefits from cancer treatment.No matter what Mikhail Blagosklonny has done in the past, he does not have all of the answers to cure cancer. He has tried his hardest to make sure that he can help people with the cancer treatment that they deserve but he also wants to make sure that he can give them the positive parts of the cancer treatment so that they don’t have to rely on the help from other people. He hopes that, one day, Oncotarget will be able to allow the doctors to come together and come up with the cure for cancer.